Document is current
Any future updates will be listed below
-
Authors
Zhang, Xiaoyun https://orcid.org/0000-0002-4132-3573
Dhir, Somdutta
Melidis, Larry https://orcid.org/0000-0001-6853-2722
Chen, Yuqi
Yu, Zutao https://orcid.org/0000-0003-1389-0818
Simeone, Angela
Spiegel, Jochen https://orcid.org/0000-0001-7641-1066
Adhikari, Santosh
Balasubramanian, Shankar https://orcid.org/0000-0002-0281-5815
-
Funding
Funding for this research was provided by:
Cancer Research UK (C9681/A29214, SEBINT-2024/100003)
Wellcome Trust (209441/Z/17/Z)
Herchel Smith Funds
- License Information
-
More Information
Article History
Received: 23 May 2024
Accepted: 4 March 2025
First Online: 3 April 2025
Competing interests
: S.B. is a founder and shareholder of biomodal, GenomeTx, Elyx and RNAvate. L.M. is a paid consultant for GenomeTx. A.S. is an employee of QIAGEN. J.S. is an employee of GenomeTx. S.A. is an employee of BenevolentAI. The other authors declare no competing interests.
